Maze Therapeutics, Inc. (MAZE) Stock Forecast & Price Target

Compare

57 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MAZE Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Maze

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MAZE Stock 12 Month Forecast

Average Price Target

$49.29

▲(18.17% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Maze Therapeutics, Inc. in the last 3 months. The average price target is $49.29 with a high forecast of $60.00 and a low forecast of $37.00. The average price target represents a 18.17% change from the last price of $41.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","61":"$61","21.25":"$21.3","34.5":"$34.5","47.75":"$47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,21.25,34.5,47.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.6,39.323076923076925,41.04615384615385,42.769230769230774,44.49230769230769,46.215384615384615,47.93846153846154,49.66153846153846,51.38461538461539,53.107692307692304,54.830769230769235,56.55384615384615,58.276923076923076,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.6,38.49923076923077,39.39846153846154,40.29769230769231,41.19692307692308,42.09615384615385,42.995384615384616,43.894615384615385,44.793846153846154,45.69307692307692,46.59230769230769,47.49153846153846,48.39076923076923,{"y":49.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.6,37.55384615384615,37.50769230769231,37.46153846153846,37.41538461538462,37.36923076923077,37.323076923076925,37.276923076923076,37.23076923076923,37.184615384615384,37.13846153846154,37.09230769230769,37.04615384615385,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$49.29

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rami Katkhuda

LifeSci Capital

$57

Buy

36.66%

Upside

Initiated

12/20/25

Analysts' Top Healthcare Picks: Novan (NOVN), Maze Therapeutics, Inc. (MAZE)

Debjit Chattopadhyay

Guggenheim

$34→$46

Buy

10.29%

Upside

Reiterated

12/19/25

Guggenheim Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE)

Sadia Rahman

Wells Fargo

Not Ranked

Wells Fargo

$55

Buy

31.86%

Upside

Initiated

12/04/25

Maze Therapeutics initiated with an Overweight at Wells FargoMaze Therapeutics initiated with an Overweight at Wells Fargo

Ananda Ghosh

H.C. Wainwright

$50→$60

Buy

43.85%

Upside

Reiterated

12/03/25

Maze Therapeutics price target raised to $60 from $50 at H.C. WainwrightMaze Therapeutics price target raised to $60 from $50 at H.C. Wainwright

Martin Auster

Raymond James

$48

Buy

15.08%

Upside

Initiated

11/13/25

Raymond James Initiates a Buy Rating on Maze Therapeutics, Inc. (MAZE)

Anupam Rama

J.P. Morgan

$37→$42

Buy

0.70%

Upside

Reiterated

11/12/25

Maze Therapeutics, Inc. (MAZE) Receives a Buy from J.P. Morgan

Julian Harrison

BTIG

$37

Buy

-11.29%

Downside

Reiterated

10/01/25

Analysts' Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN)

Joseph Schwartz

Leerink Partners

$28→$34

Buy

-18.48%

Downside

Reiterated

09/15/25

Maze Therapeutics price target raised to $34 from $28 at LeerinkMaze Therapeutics price target raised to $34 from $28 at Leerink

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

08/13/25

Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials

Laura Chico

Wedbush

$17

Buy

-59.24%

Downside

Reiterated

08/01/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rami Katkhuda

LifeSci Capital

$57

Buy

36.66%

Upside

Initiated

12/20/25

Analysts' Top Healthcare Picks: Novan (NOVN), Maze Therapeutics, Inc. (MAZE)

Debjit Chattopadhyay

Guggenheim

$34→$46

Buy

10.29%

Upside

Reiterated

12/19/25

Guggenheim Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE)

Sadia Rahman

Wells Fargo

Not Ranked

Wells Fargo

$55

Buy

31.86%

Upside

Initiated

12/04/25

Maze Therapeutics initiated with an Overweight at Wells FargoMaze Therapeutics initiated with an Overweight at Wells Fargo

Ananda Ghosh

H.C. Wainwright

$50→$60

Buy

43.85%

Upside

Reiterated

12/03/25

Maze Therapeutics price target raised to $60 from $50 at H.C. WainwrightMaze Therapeutics price target raised to $60 from $50 at H.C. Wainwright

Martin Auster

Raymond James

$48

Buy

15.08%

Upside

Initiated

11/13/25

Raymond James Initiates a Buy Rating on Maze Therapeutics, Inc. (MAZE)

Anupam Rama

J.P. Morgan

$37→$42

Buy

0.70%

Upside

Reiterated

11/12/25

Maze Therapeutics, Inc. (MAZE) Receives a Buy from J.P. Morgan

Julian Harrison

BTIG

$37

Buy

-11.29%

Downside

Reiterated

10/01/25

Analysts' Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN)

Joseph Schwartz

Leerink Partners

$28→$34

Buy

-18.48%

Downside

Reiterated

09/15/25

Maze Therapeutics price target raised to $34 from $28 at LeerinkMaze Therapeutics price target raised to $34 from $28 at Leerink

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

08/13/25

Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials

Laura Chico

Wedbush

$17

Buy

-59.24%

Downside

Reiterated

08/01/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Maze Therapeutics, Inc.

1 Month

xxx

Success Rate

5/5 ratings generated profit

Average Return

+27.64%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +27.64% per trade.

3 Months

xxx

Success Rate

6/6 ratings generated profit

Average Return

+60.23%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +60.23% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

5/5 ratings generated profit

Average Return

+266.62%

reiterated a buy rating 4 months ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +266.62% per trade.

2 Years

xxx

Success Rate

5/5 ratings generated profit

Average Return

+266.62%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +266.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MAZE Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MAZE has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MAZE average Analyst price target in the past 3 months is 49.29.

Each month's total comprises the sum of three months' worth of ratings.

MAZE Financial Forecast

MAZE Earnings Forecast

Next quarter’s earnings estimate for MAZE is -$0.70 with a range of -$0.80 to -$0.63. The previous quarter’s EPS was -$0.66. MAZE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MAZE has Performed in-line its overall industry.

No data currently available

MAZE Sales Forecast

Next quarter’s sales forecast for MAZE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MAZE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MAZE has Performed in-line its overall industry.

MAZE Stock Forecast FAQ

What is MAZE’s average 12-month price target, according to analysts?

Based on analyst ratings, Maze Therapeutics, Inc.’s 12-month average price target is 49.29.

What is MAZE’s upside potential, based on the analysts’ average price target?

Maze Therapeutics, Inc. has 18.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MAZE a Buy, Sell or Hold?

Maze Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Maze Therapeutics, Inc.’s price target?

The average price target for Maze Therapeutics, Inc. is 49.29. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $37.00. The average price target represents 18.17% Increase from the current price of $41.71.

What do analysts say about Maze Therapeutics, Inc.?

Maze Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of MAZE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Maze Therapeutics, Inc. (MAZE) Stock Forecast & Price Target

MAZE Analyst Ratings

MAZE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Maze Therapeutics, Inc.

MAZE Analyst Recommendation Trends

MAZE Financial Forecast

MAZE Earnings Forecast

MAZE Sales Forecast

MAZE Stock Forecast FAQ

Detailed List of Analyst Forecasts